This is also the first study to examine the pharmacological effect of 8-Br-ADPR and N6-Bnz-cAMP drug treatments on TRPM2 and CD38 surface expression, as well as NK cell cytotoxicity in ME/CFS patients. Here, CD38 is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.